Roche

AbbVie’s Venetoclax receives FDA Breakthrough Therapy designation for CLL

Thursday, May 7, 2015 12:54 PM

AbbVie has announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

More... »

Quest Diagnostics

Curadev, Roche ink research cancer immunotherapeutic collaboration

Wednesday, April 22, 2015 12:13 PM

Curadev Pharma, headquartered in New Delhi, India, has entered into a research collaboration and exclusive license agreement with Roche for the development and commercialization of IDO1 and TDO inhibitors. The agreement covers the development of the lead preclinical immune tolerance inhibitor and a research collaboration with Roche's research and early development organization to further explore the IDO and TDO pathways.

More... »


Roche acquires CAPP Medical, strengthens oncology translational research pipeline

Monday, April 13, 2015 12:18 PM

Roche has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and located in Palo Alto, Calif., to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood.

More... »

Roche becomes majority shareholder in Foundation Medicine

Thursday, April 9, 2015 01:41 PM

Roche has become a majority shareholder of Foundation Medicine, a molecular information company based in Cambridge, Mass. Roche purchased approximately 15.6 million shares of common stock through a tender offer from Foundation Medicine stockholders at a price of $50 per share.

More... »

Clinicians, researchers and industry collaborate with the 100,000 Genomes Project

Friday, March 27, 2015 11:12 AM

Genomics England has announced a new collaboration as part of the 100,000 Genomes Project to accelerate the development of new diagnostics and treatments for patients. Ten pharma and biotech companies have come together to create the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long industry trial.

More... »

Roche, BioMed X collaborate to develop nanomaterial-based biosensors

Thursday, February 26, 2015 03:30 PM

Roche and BioMed X, a collaboration model at the interface between academia and industry based in Heidelberg, Germany, have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene.

More... »

FDA grants Genentech’s cobimetinib Priority Review for melanoma

Thursday, February 19, 2015 01:00 PM

The FDA has accepted and granted Priority Review for Genentech’s, a member of the Roche Group, NDA for cobimetinib in combination with Zelboraf (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma. The FDA will make a decision on approval by Aug. 11.

More... »

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015 12:20 PM

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

More... »

Roche, Qualcomm collaborate to innovate remote patient monitoring

Friday, February 6, 2015 12:29 PM

Qualcomm's subsidiary, Qualcomm Life, and Roche, a Swiss-based provider of point-of-care diagnostics, have entered into a strategic collaboration to improve remote monitoring and management of chronic disease patients.

More... »

Inovio appoints Mark Gelder vice president, clinical development

Thursday, January 29, 2015 01:09 PM

Inovio Pharmaceuticals has appointed Mark Stephen Gelder, M.D., as vice president, clinical development. Gelder will be responsible for planning and executing Inovio's clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio's chief medical officer.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs